Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma

Hepatobiliary Surg Nutr. 2022 Aug;11(4):592-596. doi: 10.21037/hbsn-22-143.
No abstract available

Publication types

  • Editorial